- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05687526
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
August 31, 2023 updated by: RemeGen Co., Ltd.
A Phase 1, Open-label, Multi-center, Multiple-dose Study to Evaluate the Pharmacokinetics of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
This is a multi-center, open-label, phase 1 study.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the pharmacokinetics (PK) of multiple doses of Telitacicept in subjects with childhood-onset systemic lupus erythematosus (cSLE) on a background of standard of care therapy and explore the safety and efficacy of Telitacicept in patients with cSLE.
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Binghua Xiao
- Phone Number: 86-101-58076833
- Email: binghua.xiao@remegen.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Not yet recruiting
- Peking Union Medical College Hospital
-
Beijing, Beijing, China
- Not yet recruiting
- Children's Hospital of Capital Institute of Pediatrics
-
-
Chongqing
-
Chongqing, Chongqing, China
- Not yet recruiting
- Children's Hospital of Chongqing Medical University
-
-
Henan
-
Zhengzhou, Henan, China
- Not yet recruiting
- Henan Children's Hospital
-
-
Hunan
-
Changsha, Hunan, China
- Recruiting
- Hunan Children's Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Not yet recruiting
- Nanjing Children's Hospital
-
-
Jilin
-
Changchun, Jilin, China
- Not yet recruiting
- The First Hospital of Jilin University
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- Not yet recruiting
- Xi'an Children's Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China
- Not yet recruiting
- Children's Hospital of Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, China
- Recruiting
- Chengdu Women's & Children's Central Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Children's Hospital of Zhejiang University School of Medicine
-
Wenzhou, Zhejiang, China
- Recruiting
- The Second Affiliated Hospital of Wenzhou Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Main Inclusion Criteria:
- Fulfills SLICC 2012 or 2019 EULAR/ACR classification criteria for SLE.
- 12-17 years of age when signing the informed consent.
- Parent or legal guardian provided written informed consent.
- SELENA SLEDAI score ≥ 8 at screening.
- Serum autoantibodies (ANA and/or anti ds-DNA) tested positive at screening.
- Have been on a stable standard of care for SLE for at least 30 days prior to randomization.
Main Exclusion Criteria:
- Have received Telitacicept at any time.
- Have received any of the following therapies within 6 months of baseline: B-cell targeted treatment, e.g., belimumab, rituximab, abatacept, other investigational biologicals.
- Have received any of the following therapies within 90 days of baseline: anti-TNF or anti-IL-6 therapy, interleukin-1 receptor antagonist, intravenous immunoglobulin (IVIG), plasmapheresis.
- Have received any of the following therapies within 30 days of baseline: Intravenous cyclophosphamide, non-biological investigational agents (within 30 days of baseline or 5 half-lives, whichever is longer), newly added immunosuppressive/immunomodulatory agent, anti-malarial, NSAID, high-dose prednisone or equivalent (> 1.5 mg/kg/day) or any intramuscular or intravenous steroid.
- Have received live vaccine within 30 days of baseline.
- Participated in an interventional clinical trial within 6 months of screening.
- Active CNS lupus requiring treatment within 60 days of baseline, including seizure, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis or CNS vasculitis.
- Currently on kidney replacement therapy (hemodialysis, peritoneal dialysis) or in need of such therapy within 90 days of baseline.
- eGFR<30 mL/min/1.73m2.
- Acute severe nephritis.
- History of vital organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
- Significant unstable or uncontrolled acute or chronic diseases (cardiovascular, lung, hematology, gastrointestinal, liver, renal, neurologic, malignancy or infectious disease) that could be explained by causes other than SLE.
- History of malignant neoplasm in the past 5 years.
- Primary immune deficiency.
- Acute or chronic infections requiring treatment.
- HIV/HCV/HBsAg/HBcAb positive.
- Tuberculosis.
- Have planned surgery, laboratory abnormalities, other diseases or conditions that, in the opinion of the investigator, makes the subject unsuitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Telitacicept 2.5 mg/kg
|
Subjects will be given Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
Cmax is defined as peak plasma concentration of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
tmax of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
tmax is defined as time to reach Cmax of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
Ctrough of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
Ctrough is defined as observed plasma concentration of Telitacicept just prior to the beginning of a dosing interval
|
up to 42 days following the last dose of Telitacicept
|
Cav of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
Average concentration of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
AUC0-t of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
AUC0-t is defined as area under the curve from time zero to last quantifiable concentration of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
t1/2z of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
t1/2z is defined as terminal elimination half-life of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
λz of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
λz is defined as terminal elimination rate constant
|
up to 42 days following the last dose of Telitacicept
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SLE Responder Index 4 (SRI 4)
Time Frame: Week 4, Week 8, Week 12
|
SRI 4 is defined as a. SELENA-SLEDAI score reduced from baseline by at least 4 points; b. no new BILAG A or no more than 1 BILAG B compared to baseline; c. physician's global assessment (PGA) increased from baseline by less than 0.3 points.
|
Week 4, Week 8, Week 12
|
Proportion of subjects with SELENA-SLEDAI score reduced from baseline by at least 4 points.
Time Frame: Week 4, Week 8, Week 12
|
The SELENA-SLEDAI is a tool for measuring the activity of systemic lupus.
The total score ranges from 0-105, with a higher score representing a more significant degree of disease activity.
|
Week 4, Week 8, Week 12
|
Change from baseline in PGA.
Time Frame: Week 4, Week 8, Week 12
|
The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity.
A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.
|
Week 4, Week 8, Week 12
|
Change From Baseline in IgG
Time Frame: Week 4, Week 8, Week 12
|
Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.
|
Week 4, Week 8, Week 12
|
Change From Baseline in IgA
Time Frame: Week 4, Week 8, Week 12
|
Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.
|
Week 4, Week 8, Week 12
|
Change From Baseline in IgM
Time Frame: Week 4, Week 8, Week 12
|
Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.
|
Week 4, Week 8, Week 12
|
Change From Baseline in C3
Time Frame: Week 4, Week 8, Week 12
|
Complement (C3/C4) are proteins that are part of the immune system.
|
Week 4, Week 8, Week 12
|
Change From Baseline in C4
Time Frame: Week 4, Week 8, Week 12
|
Complement (C3/C4) are proteins that are part of the immune system.
|
Week 4, Week 8, Week 12
|
Incidence of AEs
Time Frame: up to Week 12
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
|
up to Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hongmei Song, M.D., Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 25, 2023
Primary Completion (Estimated)
October 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
January 8, 2023
First Submitted That Met QC Criteria
January 8, 2023
First Posted (Actual)
January 18, 2023
Study Record Updates
Last Update Posted (Estimated)
September 6, 2023
Last Update Submitted That Met QC Criteria
August 31, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18C018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
I-Mab Biopharma Co. Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on Telitacicept 2.5 mg/kg
-
MedImmune LLCCompletedRelapsed/Refractory Aggressive B-cell LymphomasUnited States
-
Eisai Co., Ltd.Completed
-
Eisai Inc.BiogenActive, not recruitingAlzheimer's DiseaseUnited States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
Janssen Research & Development, LLCCompleted
-
RemeGen Co., Ltd.Completed
-
Janssen Research & Development, LLCCompletedRespiratory Syncytial VirusesTaiwan, Belgium, United Kingdom, Argentina, Panama
-
University of Texas Southwestern Medical CenterGlaxoSmithKlineRecruitingAL Amyloidosis | AmyloidosisUnited States
-
Janssen Research & Development, LLCCompletedVTE Prophylaxis With Anticoagulation After Total Knee Replacement SurgeryBelgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland